Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls

Completed · Not applicable

Conditions studied: Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA

In brief

This study is designed to establish the prevalence of anal squamous intraepithelial lesion (ASIL) in patients with inflammatory bowel disease (IBD) and healthy controls.

Key facts

Study ID

NCT01860963

Run by

Stanford University

People needed

310

Starts

2010-01-01

Expected to finish

2013-06-01

Last updated by the study team

2013-10-01

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• All IBD patients followed in the IBD clinic and healthy controls who are greater than 18 years old

You may not qualify if…

• History of HPV vaccination
• Pregnancy
• Other immunosuppressed states (i.e. systemic lupus erythematosus, rheumatoid arthritis, cancer, Human Immunodeficiency Virus (HIV), transplant)
• IBD patients who don't meet immunosuppression/non-immunosuppression criteria
• Inability to obtain informed consent from patient
• Previous diagnosis of ASIL or anal/rectal cancer

Where it is running

• Stanford Digestive Health Center — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.